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ABSTRACT 
Conventional drug discovery focuses on single protein targets and follows a “sequence, 
structure, and function” paradigm for selecting best protein targets to screen lead 
chemical compounds. This established paradigm simply avoids addressing directly the 
challenge of evaluating chemical toxicity and side effects until a later stage of drug 
discovery, resulting in inefficiencies and increased time and cost. We developed a new 
“network biology” perspective to assess proteins as potential drug targets using emerging 
biomolecular network data sets. To do so, we integrated several types of biological data 
for current drug targets from DrugBank, protein interaction data from the HAPPI and 
HPRD databases, literature co-citation data from PubMed, and side effects data from 
FDA-approved drug usage warnings. We used the Bayes factor and Positive Predictive 
Values to examine the use of certain network properties, such as network node degrees 
and essentiality, to predict candidate drug targets. We also developed a metric to evaluate 
a protein target’s overall side effects by taking into account aggregated side effect scores 
of all FDA-approved drugs targeting the protein. We discovered that non-essential 
protein with lower-to-medium network node degree could better serve as drug targets 
when combined with conventional protein function information. Integrated biomolecular 
associations, instead of physical interactions, are better sources for predicting drug targets 
with network biology methods. Our network biology framework presents exciting 
promises in developing better drug targets that lower the side-effects at later stages of 
drug development and help establish the field of “network pharmacology.” 
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CHAPTER ONE 
 
INTRODUCTION: BASIC CONCEPTS AND THESIS OVERVIEW 
Use of the Network Biology perspective in drug discovery would help in 
determining the way potential targets are most likely to behave, their interconnections, 
and the possible knock-out effect of interfering with them. Network Biology is an 
assembly of interconnected functional modules that integrate and coordinate the cell's 
major biochemical activities and responses to external and intrinsic signals. The theory 
predicts that modulating multiple nodes simultaneously is often required for modifying 
phenotypes[1]. The concept includes network topological properties, such as network 
centrality, clustering coefficient; network functional properties, such as 
lethality/essentiality; and dynamical properties, such as entropy, fractal, robustness and 
complexity.  
1.1 Basic Concepts: Network Biology and Drug Discovery 
The most critical step in the drug discovery process is target identification and 
validation. Current paradigm of drug discovery is single target[1-3] or selective target[4]. 
A drug target is a key molecule involved in a particular metabolic or signaling pathway 
that is specific to a disease condition or pathology, which could be modified by an 
external stimulus. The toxicity, specificity and the inability to obtain potent compounds 
against polysaccharides, lipids and nucleic acids limit the domain of drug targets mostly 
to proteins[5]. Some of the properties which differentiate a protein as a candidate drug 
target are the ability to bind to small molecules (structural property, Figure 1.1), overlap 
with disease[5], connectivity (the number of other proteins with which it interacts) and 
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between-ness (shortest path between two networks) (Figure 1.1).  These properties make 
it important to study them from the network biology perspective. Though being a single 
targeted drug discovery, the drugs have been reported to interact with several other 
proteins.  
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1:  Overview of relationship between main entities of the thesis (rectangle 
showing the scope of the thesis) 
 
For a drug to be effective it must bind to its target protein with a reasonable 
degree of potency[5]. The other properties include compliance with the ‘Rule of five’ 
(necessary molecular properties), solubility, and hydrophobicity (Figure 1.1). Drugs often 
cause side effects which have been accredited to a number of molecular scenarios (Figure 
1.1) including the interaction with the primary or additional targets (off-targets binding), 
downstream pathway perturbations, kinetic and dosage effects, and drug-drug 
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interference. Keeping these scenarios in mind while selecting targets would help 
minimize the side effects. But the current paradigm of single targeted drug discovery 
does not seem to consider the different properties of drug target proteins. To target 
proteins which are a part of complex networks, network study is of utmost importance. 
Protein interactions can be modeled as a network of nodes or components. The 
edges in the network are the physical and the functional interactions among the proteins. 
The number of interacting partners a protein has determines its Degree of Connectivity, 
which in turn classifies a protein to be a hub or a non-hub with the hubs being proteins 
that are highly connected. The node connectivity (degree) follows a power law 
distribution; i.e., there  are  a  small number of nodes with a large  number  of  
connections and a large  number  of nodes  with a small  number of  connections[6]. 
These hubs are quite stringent to random deletions. Based on the partners and the time 
and location of interaction, the hubs are further classified as date hubs and party hubs[7].  
Essentiality is one of the properties (Figure 1.1) which refers to a protein that 
when knocked out renders the cell unviable. It is the behavior of a network on deleting a 
protein which defines it to be essential or non-essential (Centrality and lethality rule [6]). 
However, there are controversies among the structural importance[6] and the functional 
importance[7] of a protein in a network which decides its essentiality. But to date, there is 
no concrete definition as to what constitutes essentiality. 
The aim of this study is to do statistical analysis on existing drug targets for their 
network properties, such as network node degrees and essentiality, with the intention of 
finding new characteristics of drug target proteins from the network perspective that 
would help in predicting candidate drug targets. Apart from high level analysis of drug 
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targets, this study analyzes in depth the network properties of drug target proteins, which 
makes them stand out in the crowd of potential targets. Finding specific node degrees of 
drug target proteins will help cut down on the large number of proteins out there and also 
would introduce new potential targets that have the characteristics for becoming good 
targets causing minimal side effects. The analysis of whether essentiality should play a 
role, or whether it has any role, in target selection or in causing side effects by drugs 
could bring a new prospective of target selection. The side effect analysis will help in 
determining which could be future good targets with minimal side effects from the 
existing targets.  
Current paradigm of drug discovery focuses on finding a ‘magic bullet’[4] for a 
disease with minimal side effects. But it avoids addressing directly the challenge of 
evaluating chemical toxicity and side effects until a later stage of drug discovery, 
resulting in inefficiencies, as well as increased time and cost, which ultimately results in 
fewer drug approvals. It also does not seem to work for complex disorders that progress 
by multiple pathways and mechanisms. Another problem is the abundance of ‘me too’ 
drugs or the same drug target protein being targeted over and over by different drugs for 
different diseases[2]. 
1.2 Motivation 
Owing to the complexity of organisms and the complex interactions its cells have 
to undergo in performing several activities, the study of potential targets in relation to 
intercellular network of interactions becomes a requirement. Today, the biggest challenge 
in drug discovery is the high attrition rate. Many drugs fail due to the poor understanding 
of the system’s molecular functions they have to target and the way they might affect the 
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entire system’s network[8]. Using the “network biology” perspective to proteins as 
potential drug targets would be a solution to the problem. 
1. We developed a network-topology-based method that would facilitate the 
evaluation of potential drug targets. 
1.3 Thesis Contribution 
We developed a novel “network biology” approach to select potential drug 
targets. This method shows a new way to select targets by using the network 
properties such as network node degrees of a protein. 
2. We developed a method for evaluating the true goodness of the drug targets. 
Through our work we show that simply selecting a target does not qualify it to be 
a ‘good target’ that would cause minimum side effects. We show how to select a 
‘good target’ by combining the network property of protein to the side effects 
caused by drugs. 
3. Our method of rating drugs based on side effects would assist in standardizing 
drugs. 
We developed a method that rates all drugs depending on the side effects they 
cause. 
4. We developed a metric to evaluate drug targets based on the side effects which 
will provide an idea of the severity of the side effects they would cause when 
targeted. 
We show a way to evaluate the target protein’s overall side effects by taking into 
account the aggregated side effect scores of all FDA-approved drugs targeting the 
protein. 
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This thesis is divided into five chapters. The first chapter deals with the 
introduction and overview and Chapter 2 discusses the literature reviews in the context of 
hubs, protein essentiality and drug targets. Chapter 3 describes the methods and formulae 
used in the study for the statistical network analysis of drug targets, as well as the data 
collection and the challenges faced in doing so. Chapter 4 analyzes the graphs and 
presents the results and Chapter 5 concludes the thesis with a discussion. 
1.4 Organization of the Thesis 
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CHAPTER 2 
LITERATURE SURVEY 
 
This chapter introduces topics that are necessary for understanding the problem and 
analyzing its results. Starting with the role of systems biology in drug discovery, the 
chapter proceeds to explore the current approaches for the process while highlighting the 
use of network biology in selecting candidate drug targets. The chapter ends with the 
problem definition and related research questions. 
2.1 Drug Discovery 
Drug discovery is the process by which drugs are discovered and/or designed. The 
most critical step in the process is the target selection, a key molecule involved in a 
particular pathway specific to a disease condition and possessing the potential of being 
modified by an external stimulus. Potential targets may, for example, be proteins whose 
genes are over-expressed or those associated with the defective proteins but are 
themselves unsuitable to be targeted by a small molecule. Drugs have to bind to these 
potential target proteins to cure a disease condition. But though crucial to the process, 
target identification is largely based on circumstantial evidence where a protein is 
selected based on its references to a disease. Traditionally, to study biology and human 
health, individual proteins and genes were investigated one at a time in order to 
understand their functionality and contribution toward a specific functional aspect of the 
organism. But this ignores the complexity of the multi-cellular organisms, which leads to 
a limited understanding of the human body and its operation and, thus, limits the 
capability to best predict, prevent, or remedy potential health problems. 
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2.2 
 
Systems Biology in Drug Discovery 
"Systems biology allows you to understand how a very dynamic system works so that 
you can find ways to target disease better than just blocking a pathway," said Howard 
Schulman, vice president of research at California-based SurroMed. 
 Systems biology forms a cycle of experiments performed, result analysis and 
novel knowledge (Figure 2.1).  
 
  
      Figure 2.1  
• In order to understand the complexity of the biological systems, it is necessary to 
perform experiments which in turn generates huge amount of data. 
• The data generated from experiments would be of no value without analysis. Thus 
computation analysis becomes crucial for the vast data generated by experiments. 
As a result, we gain new knowledge. 
• The new knowledge obtained as a result of analysis of new data is then used to 
perform new experiments, and, as such, the cycle continues. 
 Drug discovery and systems biology began as traditional folk medicine[9, 10] where 
compounds were studied, experiments were performed and the results were used to 
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perform new experiments. Today, systems biology deals with understanding physiology 
and disease at the molecular pathway level; within regulatory networks, cells, tissues, 
organs; and ultimately the whole organism. 
• the search for disease-related targets 
An Omic approach to systems biology 
focuses on genes, proteins, and metabolites. The drug industry also has started to 
implement these Omic approaches to complement traditional approaches of target 
identification in generating hypotheses and for experimental analysis. Advances in 
systems biology suggest that complex diseases may not be effectively treated by 
interventions at single nodes only[1]. Two central problems of drug discovery today 
are:[11]- 
• the study of drug–protein interactions and protein–protein interactions 
With the huge amount of data produced from genome sequencing, systems biology 
promises to help solve the problems by uncovering new drug targets.  
Hopkins et al introduced the concept of ‘Druggability’ in the paper, ‘The 
druggable genome’[5]. The authors revealed that out of four types of macromolecule, 
namely lipids, nucleic acids, polysaccharides, and proteins (which can be interfered with 
using small-molecule therapeutic agents), it is mainly proteins that can be used as 
targets. But neither all proteins are ‘druggable,’ nor can all be targeted by drugs; only 
proteins that have the ability to bind and also overlap to a disease can be targeted. 
Drug discovery today mainly focuses on the single-target approach: ‘One target, one 
drug and one disease’[1] with the drug acting as a selective 'key' that fits into the 'lock' of 
2.3. Current Approach to Drug Discovery 
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a specific drug target. Despite the fact that the target-based paradigm eases certain 
development activities, it also has certain drawbacks, as follows: 
• It isn’t always guaranteed to work. It might not always affect complex systems in 
the desired way even if it completely changes the behavior of its immediate 
target.[8] 
• Certain drugs work only for a certain population of patients. – Iressa works only 
within a particular population. It gives a good response in only 1/10 of the 
patients who receive it [3, 12]. 
•  It ignores the enormous complexity of cells and tissues. For example, single 
targets might have ‘back-up’ systems which could sometimes be different and 
may not  respond to the same drug[8]. 
• It limits the ability of researchers to identify innovative targets and/or 
mechanisms of action (including combination therapies) by limiting druggable 
space to recognized targets and modalities[9]. 
• It usually cannot fight multi-genic diseases such as cancer, or diseases that affect 
multiple tissues or cell types. Cancer and other nervous system defects are 
deregulation of many biochemical pathways. 
However, the fact that the drugs bind to several other targets is often ignored. For 
example, Gleevac which is developed using a single target approach actually works by 
attaching to a key part of an overactive protein that causes chronic myeloid leukemia [4]. 
While studying antipsychotic drugs, it was found that the successful drugs actually act on 
multiple, rather than single, targets. 
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Yildirim, M.A., et al[2], in their ‘Drug-Target Network’ study, developed a 
network of current drugs and their targets. Through their analysis of the network they 
revealed that though maximum drugs have only one target, there are several drugs which 
have multiple targets (Figure 2.2(a)) and many drug target proteins are, in turn, being 
targeted by more than one drug (Polypharmacology) (Figure 2.2(b)). 
 
(a)          (b)   
Figure 2.2 (a) Number of targets per drug (b) Number of drugs per target 
The analysis of a drug-target network also showed the abundance of `me too ` 
drugs, meaning the old targets were being targeted again and again[2]. When mapping 
the drug-target network to a human disease-gene network, it was found that not only did 
the drugs act on multiple targets, but the targets also were involved in multiple 
diseases[1]. Thus, although the current approach of drug discovery may be single 
targeted, behind the scenes the drugs also act on other targets and those targets are not 
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being considered. It has also been found that 30% to 40% of drugs fail in clinical trials 
because of inappropriate target selection[5]. This clearly indicates that the current 
paradigm of drug discovery needs to be revisited. 
Another market study on the rate of drug approvals showed that although there is a 
continuous increase in the cost per experiment performed, the rate of drug approvals are 
on declining, which should not be the case, given the enormous increase in resources and 
advancement in the research technologies.   
Viewing drug action through the lens of network biology may provide insights 
into improving drug discovery for complex diseases[1]. The study of network biology in 
relation to targets becomes of utmost importance considering the complexity of cells and 
tissues and the fact that drugs act on multiple targets at the same time. Hopkin’s et al. in 
their ‘Network Pharmacology’ study, mapped the drug target network on the protein 
interaction network to reveal all the proteins be targeted by the same drug and their 
interconnection. They stressed the fact that drug efficacy and toxicity can be well 
understood by action at specific nodes and hubs.   
Side effects are harmful and undesired results from a medication or other 
intervention. They are complex phenomenological observations that have been attributed 
to a number of molecular scenarios, including interaction with the primary or additional 
targets (off-targets hereafter), downstream pathway perturbations, kinetic and dosage 
effects, and drug-drug interference. After a drug enters a cell, it can either interact 
directly with a receptor or evoke beneficial or detrimental responses by either up- or 
down-regulation of receptor-activated signaling pathways. Or the drug can undergo 
2.4 Drugs and their Side Effects 
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metabolism to products that, in turn, react with the receptor. The majority of these 
products are inactive (detoxification), but some are reactive and bind[13]. 
Of all causes, off- target binding is the most important. It has been found that 
Viagra was designed to target PDE-5 and promote the relaxation of smooth muscle, but 
the compound also binds to the homologous PDE-6 in the eye, which leads to a “blue 
vision” side effect in patients[14] (Figure 2.3a). This shows the necessity of studying the 
targets relevant to the network. The network approach examines the effect of drugs in 
the context of a network of relevant protein-protein interactions.[8] This could help 
minimize severe side effects. While doing the network analysis of serotonin receptor 
(HTR4 and HTR2A) with its agonist cisapride, Kuhn et al[15] found that cisapride also 
binds to the cardiac ion channel hERG (KNCH2) (Figure 2.3b), which leads to 
arrhythmias as a side effect. In addition, the network also showed the interaction of 
cisapride with Cytochrome P450 enzymes (CYP3A4 and CYP2D6).  
 
   
          
(a)             (b)                                                
Figure 2.3: (a) Example of off-target binding by Apic, G. et al.  (b) Sources of 
interaction shown by color experiments (red) and text mining (blue)  
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However, due to limitations related to the availability of data, not much has been done 
toward studying the co-relation of drugs, targets and their side-effects on a large scale. It 
is most likely that novel associations between drugs and protein targets could be 
found by comparing the side effects profiles of drugs[15]. 
Proteins are often referred to as the molecular workhorses of the cell since they 
are responsible for the majority of functions within a living cell. Protein networks help 
define individual proteins within the context of all other cellular proteins[16]. They form 
a network of interacting proteins where components or nodes (proteins) are connected by 
physical and functional interactions (edges)[6]. Based on the degree of connectivity, the 
proteins are divided into hubs and non-hubs with hubs being the proteins having a large 
number of connecting partners. However, there is no clear cut-off degree for 
differentiating a hub from a non-hub. Some researchers have defined them as proteins 
with more than 5 interacting partners ( degree >= 5) [6, 17], whereas others have defined 
them as proteins that are in the top 20% of the degree distribution (i.e. that have the 20% 
highest number of neighbors)[18]. The node connectivity (degree) follows a power law 
distribution, i.e. there  are  a  small number of nodes with a large  number  of  
connections and a large  number  of nodes  with a small  number of  connections[6]. 
According to the ‘Centrality and Lethality Rule’ (see introduction), there exists a co-
relation between a node's structural importance in the PPI network and its functional 
importance[6]. The network analysis has shown that the removal of a hub increases the 
proportion of unreachable pairs in the network (network diameter)[19], and thus  
increases the mean shortest path between all pairs of reachable nodes in the network. 
2.5 Protein Networks 
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Haiyuan et al[18] defined network nodes that have many “shortest paths” going through 
them as ‘Bottlenecks’(proteins with a high betweenness centrality). These were believed 
to control most of the information flow in the network, representing the critical points of 
the network. Han et al[7] further divided the hubs into ‘date hubs’ and ‘party hubs’ based 
on the location and their interacting partners. Date hubs bind to different partners at 
different times or locations. They organize the proteome, connecting biological 
processes, or modules, whereas party hubs interact with most of their partners 
simultaneously. They function inside modules. Haiyuan et al believed that bottlenecks 
with high degrees should have a higher tendency to be date hubs[18]. While studying the 
characteristics of hubs and non-hubs 
Studying the position of proteins in the biological networks also could be helpful 
in drug target selection[1].  When mapping the drug-target network to the human protein 
interaction network, it was found that drug targets tend to have more interactions than 
average proteins but fewer as compared to essential proteins [1, 2]. The mapping of drug 
targets to the interaction network also would reveal all the proteins targeted by the same 
drug and their interconnection. This would be helpful in understanding how the drug 
reacts at specific nodes and would in turn be helpful in understanding the efficiency and 
the toxicity of the drug[1] 
Ekmann et al [20] found that hubs actually are multi 
domain long proteins which differentiate them from non-hubs, whereas long disordered 
regions in date hubs help them in flexible binding. 
Essential/Lethal proteins are the proteins which, when knocked out, render the 
cell unviable. Despite numerous studies performed, it is still unclear as to what causes a 
2.6 Essentiality/Lethality 
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protein to be essential or non-essential. According to Jeong, H., et al[6],  hubs tend to be 
essential. In their study they indicated that there exists a correlation between a node's 
structural importance in the PPI network and its functional importance. According to 
them, highly connected proteins with a central role in the network's architecture are three 
times more likely to be essential than proteins with only a small number of links to other 
proteins. 
  However He X, Zhang[17] challenged their results by saying that the essentiality 
of a PPI does not seem to be determined by network structures but rather by the particular 
functions of the interaction. According to them, proteins linked by an essential interaction 
must be essential, whereas an interaction between essential proteins (IBEP) may or may 
not be essential. They further demonstrated that betweenness and closeness measure the 
centrality of a node in the global network structure. Haiyuan et al[18], in their study, 
revealed that ‘bottlenecks’(proteins with a high betweenness centrality) tend to be 
essential. On finding a correlation between degree of connectivity and betweenness they 
went further to analyze a better predictor of essentiality among two. It was found that 
betweenness was a better predictor for regulation networks, whereas degree was a better 
predictor in interaction networks.   Tew et al [21], in their study, revealed that although 
the essentiality/lethality of a protein could be found based on the topological position in 
the network, lethality correlates more strongly with its "functional centrality" than pure 
physical interaction-based centrality. Goh et al[22], while studying a network of human 
genes and diseases, found that, although essential, human genes are likely to encode hub 
proteins, but that the majority of disease genes still are nonessential and show no 
tendency to encode hub proteins. Their expression pattern indicates that they are localized 
17 
 
in the functional periphery of the network. Apic et al[14] indicated that essential hub 
proteins have the potential to become future drug targets, for instance, in cancer research. 
 Existing studies have indicated that there is a need to change the current strategy 
of target selection in drug discovery that is not successful in combating all types of 
diseases. A continuous decline in drug approvals indicates an immediate need to update 
the characteristics of candidate drug targets. The importance of the network biology 
prospective in drug discovery has been recognized by some researchers but is still not 
fully implied. Hubs are being indicated as being better targets but the definition of a hub 
is still undecided or unclear. Just indicating hubs as targets opens up a large domain of 
network node degrees for candidate drug targets. There is a need to go into specific 
details on what makes the drug target proteins stand out in the crowd.  Essentiality is 
another important network characteristic of a protein but whether it is really considered 
during target selection or what affect it has on the side effects of drugs is still unknown. 
2.7 Problem Statement and Research Questions 
In my effort to address some of the problems above, I integrated the drug target, 
drug side effect and protein interaction networks to study the underlying relationships 
(Figure 2.4).  
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Figure 2.4: Focus points of the thesis 
Some questions that will be addressed in the study (Figure 2.5) are:  
 Are network hubs/non-hubs preferentially used at drug targets? 
 Which network connectivity range of proteins could be better candidates for 
targets?  
 Does the selection of a protein as a target qualify it to be ‘good target’? 
 Will network analysis help in finding ‘good targets’? 
 Does essentiality play a role in drug target selection? 
 Is there a relationship between the essentiality of targets and the side effects of 
drugs? 
 Is it possible to find ‘bad targets’ by analyzing drugs and their side effects? 
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  Figure 2.5: Thesis questions 
  
In this study we use the network biology approach to analyze current drugs, their 
targets and drugs side effects, with emphasis on network properties, such as network 
node degrees and essentiality. The idea is to study the trend in successful drugs, intending 
to discover network characteristics that might be helpful in the drug target research and 
may have been overlooked causing the decline in drug approvals. This would also bring 
forward new proteins of interest which may not have been considered before but could be 
good candidates for drug targets. Intermingling the side effects and the network 
properties would help us find characteristics of potential drug targets with greater 
probability of causing minimal side effects if targeted. 
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CHAPTER 3 
  MATERIALS AND METHOD 
 
The previous chapter discussed the literature related to drugs and drug target 
proteins, which leads to questions most likely answerable through network analysis. The 
chapter gave an overview of studies performed in relation to drug targets, protein-protein 
interactions and the essentiality of proteins. This chapter describes in detail the data 
sources of the bio-molecular network data sets used in the study, along with the method 
followed to analyze those data sets with a “network biology” perspective to assess 
proteins as potential drug targets. The objective of the approach is to find promising 
characteristics in developing better drug targets that minimize side effects. This would 
also bring forth a new perspective of analyzing drugs in connection with their targets and 
the side effects.  
 Figure 3.1 shows the data integration framework of the study. It gives the 
overview of all the data sources and the type of data acquired from them and how they 
were linked to perform the study. 
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Figure 3.1: Data Integration Framework 
3.1.1 Drug and Target Data Collection 
3.1 Drug and Drug Target Data  
Drug data was downloaded from DrugBank (http://www.drugbank.ca/) in 
2006[23]. DrugBank is a web-enabled, searchable and comprehensive source that 
combines detailed drug data (i.e. chemical) with comprehensive drug target (i.e. protein) 
information. There are more than 4,100 drug entries that include FDA-approved small 
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molecule drugs, biotechnology drugs and experimental drugs. More than 30 fields 
describe each drug, which details such information as its generic name, indication, drug 
type, molecular weight, toxicity, etc. Drug targets are described with their target name, 
gene name, Uniprot ID, etc. The drug target proteins map to the drugs by the DrugBank 
accession number. Initial analysis of the data revealed that there were a few Drugbank 
accession numbers that did map to drug target proteins and there were a few of them 
where the drug fields were not properly annotated (see appendix). These particular cases 
were discarded. Uniprot ID was decided to be the universal ID for representing the drug 
target proteins in the study, so only those drug targets that were identified by the Uniprot 
IDs were considered in this study.  We created a mapping table in order to map the drugs 
to their targets (identified by Uniprot IDs) (Figure3.1).   
3.1.2 DrugBank Data Details 
Of the 2,394 drug target proteins identified by Uniprot ID, 2,377 could be mapped 
to drugs. The 2,394 targets consist of 842 human and 1,552 non-human proteins. Of the 
4,247 total drugs, only 3,859 could be mapped to targets; those consisted of 1,062 FDA-
approved drugs and 2,797 Experimental Drugs (Figure 3.2). An initial analysis of the data 
showed most of the drugs had only one target, although there also were a significant 
number of drugs targeting multiple proteins (Figure 2.2(a)).  In the same lines, it was 
found that although most of the proteins were being targeted by only one drug, there were 
some which were targets of more than one drug (Figure 2.2(b)). DrugBank also annotates 
the target proteins with the essentiality information. Of 532 unique proteins with 
essentiality info in DrugBank, 32 were essential human proteins (Figure 3.6).     
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   Figure 3.2: Drugbank’s drug-target data mapping 
3.2.1 Essentiality Data Collection 
3.2 Essentiality Database 
The essentiality database was created by combining data from three different sources:  
1. Human essential proteins obtained from the Gandhi et al paper [24]. 
2.  DrugBank[23] also had the essentiality information for some target proteins. The 
data was, therefore, queried to extract the list of proteins with their essentiality 
information.  
3. Mouse Human orthologs essentiality data- Essential proteins data was 
downloaded from the MGD database in 2008. The proteins lethal to mice were 
termed as essential and others as non-essential. These were then mapped to their 
human orthologs to create a list of essential/non-essential proteins. 
The records used by the above three sources were: 
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• Gandhi et al paper[24] - 1,206 
• DrugBank[23] – 174 (human proteins) 
• MGD database - 4,575  
For the set of proteins identified by Uniprot IDs, Drugbank had a total of 361 
essential/lethal proteins and 152 non-essential/viable proteins. In terms of human 
proteins, there were 32 essential/lethal versus and 142 non-essential/viable proteins 
(Figure 3.6). Only these human proteins were included in the essentiality database.  
3.2.2 Essentiality database creation 
Initially, the essentiality database was created by combining only the first two 
sources above, but later in the process it was found that researchers used mouse human 
ortholog data[2] for the essentiality related studies. To test the bias, a comparative 
analysis was done on the essentiality data from three sources, namely our essentiality 
databases, Drugbank and MGD. The two-way comparison showed the contradiction 
between the Drugbank and essentiality data from MGD. Ninety-one percent of proteins 
that were non-essential/viable according to Drugbank were termed essential/lethal in the 
MGD database (Figure 3.3). This shows the biased nature of MGD toward lethality. 
        MGD (NE)            MGD (E) 
DrugBank (NE)  76 (=86%)  51 (=91%)  
DrugBank (E)  12(=13%)  5 (=8.9%)  
 
Figure 3.3: Comparison of MGD and DrugBank essentiality data 
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However, when comparing the essentiality data of MGD with that of our essentiality 
database, it was found that mouse was almost 50-50% yes for both essential/lethal and 
non-essential/viable, which shows the uncertainty of the data (Figure 3.4). 
 MGD (NE)  MGD (E)  
Essentiality database (NE)  145(=92%)  49(=50%)  
Essentiality database (E)  11(=7%)  48(=49%)  
 
Figure 3.4: Comparison of old essentiality database and MGD 
Consequently, the above comparison proves that the mouse human orthologs 
essentiality data is most uncertain and is more biased toward lethality/essentiality and 
could not be relied on for studying the essentiality of human proteins. Hence, to provide a 
more reliable solution, it was decided to manually integrate the data from all three 
sources and develop a new essentiality database. There were several criteria for curation. 
First, a protein would be termed as non-essential if in any of the three sources it was 
mentioned as non-essential/viable and termed as essential/lethal if the sources mentioned 
it to be lethal/essential. Second, if the information for a particular protein was not present 
in the other two sources, it would be considered as it was mentioned. But a protein would 
be dropped if it was only mentioned as lethal in MGD but absent in the other two sources 
since the MGD data was biased toward lethality/essentiality.  It was this curated database 
that was further used in the study for essential proteins and drug targets. The summary 
flowchart of the curation process is shown in Figure 3.5.  
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  Figure 3.5: Summary flowchart of new essentiality database creation 
The curated essentiality database, thus created, had a total of 3,279 proteins, of which 427 
were essential/lethal and 2,852 were non-essential/viable (Figure 3.6). The essentiality 
database is  
 
Figure 3.6: Essential and non-essential proteins in Drugbank vs. essentiality database   
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almost scale free (Figure 3.7) with a small representation of low degree proteins. But 
since it is difficult to get the data for essentiality, we could not do much about it. 
   
   Figure 3.7: Data distribution in essentiality database   
Drugs have multiple targets. In order to analyze the trend of target selection 
within drugs in terms of essentiality, the essentiality score was calculated.  
3.2.3 Essentiality Score Calculation  
  
Where: 
 No. of essential = the number of essential/lethal proteins targeted by a drug 
No. of non-essential = the number of non-essential/viable proteins targeted by a 
drug 
 Total target = the number of targets for a particular drug 
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This calculation would assist in analyzing the role of essentiality in target 
selection or to study the existing trend in drug target proteins toward essentiality. It also 
would move drugs toward targeting essential/lethal proteins or non-essential/viable 
proteins.  
 3.3.1 Interaction Data Collection  
3.3 Protein-Protein Interaction Data 
         The protein interaction data was required in order to perform the network analysis 
of drug targets for the hubs or non-hubs with emphasis on network degree of 
connectivity. The initial study was done on the subset of proteins in HAPPI database with 
the interaction score of above .75. In order to study different types of interactions, the 
data was collected from a number of other sources and the network connectivity score 
was calculated to make the study uniform across the different sources. The data sources 
considered in the study were: 
• HAPPI database for different confidence ranked interactions 
• STRING database for literature co-occurrences[25] 
• HPRD[26] 
• Pathway studio data for promoter binding  
• Reactome data for metabolic pathways[27] 
• Human co-expression[28] 
HAPPI database (Human annotated protein-protein Interaction database). 
HAPPI is a comprehensive database of nearly all known protein-protein interactions. It is 
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an integrated source that includes interactions from SwissProt, Trembl, Online Predicted 
Human Interaction Database (OPHID), literature mining, etc. and focuses on human 
protein interactions.  Based on the source of the interaction record and method of 
prediction, each interaction is assigned a confidence score between 0 and 1. The 
interactions are then provided a confidence rank of 1-5 based on their confidence scores. 
The interactions from real human protein interaction experiments were provided a high 
score of .9 (Confidence Rank 5) and those derived from mammalian organisms were 
assigned a medium score. For calculating the general degree of connectivity of proteins, 
the interactions with the confidence score (H-score) > .75 is used. There are 9,240 
interacting proteins in this range. 
Confidence Rank Confidence score (H-score) Count of interacting proteins 
Confidence Rank = 1 .1- .24 8652 
Confidence Rank = 2 .25- .44 8933 
Confidence Rank = 3 .45 - .74 9935 
Confidence Rank = 4 .75 - .89 10056 
Confidence Rank = 5 .9 - 1 5329 
 
Figure 3.8: HAPPI database data details  
STRING database[25]. This is a database of known and predicted protein-
protein interactions, including both direct (physical) and indirect (functional) 
associations. These interactions are obtained by both experimental and predicted results 
and also by literature mining. The interactions obtained by mining are linked to their 
supporting PubMed IDs. All the proteins in the database are identified by their Protein 
Ensembl ID and all the interactions could be mapped to the citation information. Two 
proteins were said to be interacting if both had the same abstract IDs. The network degree 
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of connectivity of a protein was the total number of proteins it interacted with in the cut-
off range. There were four cut offs applied based on the number of abstracts in which the 
proteins appeared together (namely 2, 3, 5 and 10).  
HPRD (Human Protein reference Database) [26]. This is a data source of manually 
curated human protein interactions consisting of physical associations. The data could be 
downloaded in the tab delimited and XML formats. The raw data contained 37,107 
interactions, which were then mapped to 6,927 proteins identified by uniprot ids. 
Human co-expression. The data was downloaded from the supplemental data of Lees et 
al[28]  published in 2004. The paper used 60 human microarray data sets totaling 3,924 
arrays to identify pairs of genes that were reliably co-expressed based on the correlation 
of their expression profiles. The data was curated and a co-expression link between two 
genes was termed confirmed if the link was observed in more than one data set. All the 
supplemental data could be downloaded in MS Excel format. Only the genes with links 
observed in at least 3 data sources were used in the study. Once the data was downloaded, 
the genes were mapped to the Uniprot IDs.  The degree of each protein was calculated by 
counting the number of co-expressed proteins for a particular protein. 
Pathway Studio (http://www.ariadnegenomics.com/products/pathway-studio/)- This is commercial 
software developed by Ariadne Genomics. It is a pathway database consisting of data 
extracted from PubMed using Med Scan and natural language processing tools. The data 
from pathway studio was downloaded in MS Excel formal, which was used to download 
the promoter binding data. The data could not be readily mapped to the corresponding 
Uniprot IDs so were not used in the study.  
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Reactome [27]. This is a database of curated human pathways. It has the information of 
several pathways including metabolism, regulatory pathways, signal transduction 
pathways, etc. The information is curated from published literature by experts. The basic 
of the Reactome database is the reactions which are grouped into pathways. The reaction 
file could be downloaded in XML format from the reactome website. For the study, only 
metabolic pathways were considered. A XML parser was written in C# to parse the 
reactants, products, and metabolites information. Since Uniprot IDs were used as the 
universal identifier for the study, the metabolites would need to be mapped to their 
UniProt representations. But this could not be successfully done so the data was not 
included in the study. 
3.3.2 Bayes Factor Calculation 
The Bayes factor, in its simplest form, is the marginal likelihood ratio given 
background information. In the study, the Bayes factor was used to investigate the 
likelihood of a hub or a non-hub to be a drug target. The formulae for Bayes factor is  
 
With M1 and M2 being the two models and x the base of comparison.  
The scale for significance of values is 
• K  < 3  (not significant ) 
• K= 3-10  (substantially significant ) 
For the study the formulae was arranged as 
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x= Drug targets (DT) 
M1=hub  
M2= non-hub  
Thus, the formulae used in the study is 
 
where probability of DT given hub and non-hub was calculated by the following 
equation: 
 
 
 3.3.3 Network Connectivity Score 
In order to unify the study across several other interaction datasets used in the study, a 
network connectivity score was calculated. The formulae for the score is 
  
where X is the percentage of proteins at a particular network node degree range. As each 
database focuses on different types of interactions and thus have different network node 
degree for proteins, the network connectivity score would facilitate unifying the results. 
Since there is still no comprehensive source for the drug side effects data, it was 
decided to use the FDA site to pull out the data as it was the most reliable source. But the 
3.4 Drug Side Effects Data 
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site does not contain the side effects for all the drugs; as a result the data obtained were 
quite limited.  
 
Figure 3.9 Snapshot of FDA website 
(http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm) 
 
The site provides a list of drugs along with the drugs having FDA alerts on them. 
Additional information about the drugs could be found by navigating to other pages. For 
example, the related side effects. This data is not downloadable. A parser was therefore 
written in python language to parse out all the related details for the drugs. The parsing of 
the data caused a few issues as the site had to be navigated to several pages deep to 
extract the information, which were in different formats. The extracted information 
contains the index name, use, precaution, risks, warnings, side effects, etc. and the FDA 
alerts, if any, related to the 572 drugs. This data then had to be mapped to the drug data 
present in our database. The two were mapped using the drug generic name of our drug 
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data to the index name, synonyms, medicine name and marketed name from the FDA 
side effect data. Not all drugs in our database could be mapped to the side effect data.  
Also it was found that one generic name could be mapped to a couple of FDA drugs 
identified by index names (197 generic names (drugs) could be mapped to 375 index 
names (FDA).) 179/197 had the side effect information. 
3.4.1 Scoring Side Effects 
Selecting the best criteria for scoring the side effects was a problem in itself since 
there is neither any ontology for side effect terms or a general list of all types of side 
effects. Thus, it was decided to create a list from the data itself. The warnings, side 
effects and risks columns were manually searched to pull out terms describing side 
effects. These terms were given a score of 1-5 with 5 being the deadliest side effect. 
These scores were further used to score the drugs (described later in drug scoring) in 
order to develop a unified standard for drugs. FDA alerts were put on the list initially 
with the idea that the drugs having the alerts should have maximum side effects, but 
because the frequency of the alerts was high, the idea was reconsidered. On checking, it 
was found that the FDA alerts were basically alerting the physicians of possible effects 
based on dosage and drug-drug interactions, etc. So the FDA alerts were pulled out of the 
list. The final list of terms and their assigned scores are as follows: 
Symptom Score Symptom Score 
Fetal death 5  painful swelling 3 
life-threatening 5 Abnormal vision 3 
life threatening 5 Blood clot formation 3 
death 5 Dehydration 3 
Birth defects 4 High blood sugar 3 
Bleeding 4 Increased blood sugar 3 
Blood in stool 4 Pneumonia 3 
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Blood in urine 4 Severe diarrhea 3 
Possible tumor growth 4 Shortness of breath 3 
Stroke 4 Slow heart rate 3 
Symptoms of congestive heart 
failure 
4 Vomiting 3 
can cause significant nerve damage 4 abnormal movements 3 
cause leukemia 4 anemia 3 
damage 4 blurred vision 3 
depression 4 decrease in bone marrow 
production 
3 
failure blood clot 4 developed liver problems 3 
may cause death 4 diarrhea 3 
may worsen 4 hallucinations 3 
possible development of lymphom 4 hot flashes 3 
risk of serious liver injury and even 
death 
4 hypoglycemia 3 
seizures 4 leukopenia 3 
serious allergic reaction 4 low blood pressure 3 
serious breathing problems 4 low platelet count 3 
serious condition 4 low red blood cell count 3 
serious liver problems 4 myelosuppression 3 
serious side effects 4 weaken your body's immune 
system 
3 
serious ulcers 4 pain 2 
severe allergic reaction 4 rash 2 
side effects can be severe 4 tremors 2 
worsening blood disorder 4 nervousness 2 
worsening of psoriasis 4 numbness 2 
risk of bronchospasm 3 underactive thyroid 2 
nose bleeds 3 urgent bowel movements 2 
Confusion 2 redness of the eye 1 
Cramps 2 loss of appetite 1 
Fever 2 runny nose 1 
Oily discharge 2 sleepiness 1 
Swelling 2 sore throat 1 
Vision problems 2 tiredness 1 
burning 2 trouble sleeping 1 
dizziness 2 weakness 1 
fast heartbeat 2  Cold-like symptoms 1 
flushing 2  loss of sleep 1 
hair loss 2  red eyes 1 
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impotence 2 Anxiety 1 
infection 2 Breast tenderness 1 
joint problems 2 Cough 1 
mild to moderate 2 Excessive sweating 1 
mouth sores 2 Fatigue 1 
Nausea 2 Gas 1 
Headache 1 dry eye 1 
Indigestion 1 headache 1 
Menstrual changes 1 itching 1 
Sweating 1 restless 1 
chills 1 well tolerated 0 
constipation 1 Not reported  0 
  
    Figure 3.10 Side effects scoring scheme 
The scoring was subjective based on personal understanding of the seriousness of 
the term, but there was no other proven scoring method available.  
3.4.2 Drug Score Calculation 
The drugs were to be given an effect-score based on the side effects terms. For 
this, the terms were searched in the warnings, side effects, and FDA alert annotations for 
the drugs. Based on terms found in the search, the drugs were given a score. As a result, a  
drug(i) would have several effect scores (ISE) (Figure 3.11), as more than one term could 
be found in the description of side effects of drugs. Figure 3.12 shows the drug score 
calculation in context with the example used in Figure 3.11. 
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Figure 3.11: Figure showing the concept used to calculate the drug and target 
scores  
 
Figure 3.12: Drug and target score calculation 
So the the maximum of all ISE scores for a drug(i) was taken as the drug score and 
termed as GISE of a drug(i) (Figures 3.11 and 3.12). This was used as a unified standard 
for drugs based on the side effects. The GISE ranged from 1-5 with 5 being given to the 
drug that had the worst life threating side effect . 
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Since each drug targets more than one protein, the drug side effects should be the result 
of all the proteins it is targeting. Therefore, the drug score (GISE) was divided among all 
its targets (Figure 3.10). This was known as the partial probability of protein in sharing 
the side effect, termed PISE of target (Ti). It was calculated by the formulae (Figure 3.12) 
                                      
 
         The target scores were calculated in order to rank the targets based on the side 
effect scores. They were based on the scores provided by the drugs to target proteins. 
Different types of scores based on PISE values were calculated to analyze the results. 
Following is the formulae for target score calculation, as well as examples in Figure 3.12 
of values being calculated using the Figure 3.11. 
3.4.3 Target Score Calculation 
  Total side effect index for target (TISE)  
     
 
Average side effect index for target (ATISE) 
                                           
Maximum side effect index for target (MISE) 
                                           
Weighted side effect index for target (WISE) 
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These scores were used to characterize the already targeted proteins that would be used in 
calculating the Positive Predictive Value (PPV) for measuring the true goodness of the 
predicted potential targets. The target score ranged from 1-5 with 1 causing the least and 
5 causing the worst life threatening side effects. 
 The PPV is the measure that reflects the probability that a positive test reflects the 
underlying condition being tested for. It is calculated by the following formulae:    
                        
3.5 Positive Predictive Value (PPV) 
Where  
TP = proteins which fall within the particular network connectivity score and 
have target score <= 2 (less severe side-effects)  
FP = proteins which fall within the particular network connectivity score but has 
the target score >= 4 (life threatening side-effects) 
The PPV was calculated in order to test the true goodness of the predicted targets of the 
study.  An example of a PPV calculation for a connectivity score of .079 - .72 for true 
goodness (low side effect) is as follows (values from Figure 3.13): 
  PPV =   = .66  
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Range(total proteins)  .079 - .72 (75)  .78 - .94(32)  .95 - 1(3)  
Side effect score  <= 2  >=4  <= 2  >=4  <= 2  >=4  
MISE  43  22  15  12  3  0  
WISE  44  19  15  9  3  0  
 
   Figure 3.13 Example table for PPV calculation 
 
The biggest challenge we faced in data collection was the mapping of the 
different source IDs to Uniprot IDs (ID used for the study). Some of the challenges faced 
were: 
3.6 Challenges in Data Collection  
• We had to drop the analysis related to metabolic pathways and promoter binding 
because the enzymes comprised a significant amount of data that could not be 
mapped to Uniprot IDs. 
• The mapping of the side effect data with the drugs causing them was another 
problem. The index names (FDA site representation for drugs) are different from 
the generic names (DrugBank representation for drugs). Also there were many 
relationships between index and generic names. 
• The inconsistency in the format of the data at the FDA site caused severe 
problems for parsing the data. 
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• Due to the unavailability of side effects for all drugs, we had very little data for 
the analysis of ‘good targets.’  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
42 
 
CHAPTER 4 
    RESULTS AND CONCLUSION 
 
The previous chapter gave a detailed description of the biomolecular network data 
sets and their data sources used in the study. It also described the statistical network 
analysis method needed to analyze certain network properties such as network node 
degrees and essentiality on the datasets. When analyzing the drug target proteins for the 
network properties in combination with the side-effects of drugs, we reached the 
following conclusions:. 
• Essential proteins tend not to be high degree hubs (Results 4.1). 
Results 
• In current drug targets, protein interaction network hubs appear to be 
preferentially used (Results 4.2.1). 
• The preferential use of a network connectivity score by current drug targets 
depends on the choice of the interaction database (Result 4.2.4). 
• Functional interactions with higher network node degree and physical interactions 
with lower to medium node degree could prove to be better drug targets (Result 
4.2.4, discussed in a, c, d). 
• Predicting candidate drug targets does not necessarily qualify them to be ‘good 
targets.’ 
• Essentiality, in itself, does not seem to be a predictor of drug targets (Result 4.3). 
• Current drug targets seem to target more non-essential/viable proteins (Result 
4.4). 
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The chapter provides more detailed explanation of the above results. 
 Results Description 
4.1 High Degree Hubs Do Not Tend To Be Essential. 
   P(E|H in range) = 𝑝𝑝(𝐻𝐻|𝐸𝐸 𝑖𝑖𝑖𝑖  𝑟𝑟𝑟𝑟𝑖𝑖𝑟𝑟𝑟𝑟 )∗𝑝𝑝(𝐸𝐸)
𝑝𝑝(𝐻𝐻 𝑖𝑖𝑖𝑖  𝑟𝑟𝑟𝑟𝑖𝑖𝑟𝑟𝑟𝑟 )  
 
 
                 
  Figure 4.1Bayes probability of hubs to be essential 
 
In Figure 4.1, we see that the Bayes probability of a hub to be 
essential/lethal (E) is quite low (below 1.5). If the hubs tend to be essential, Bayes 
probability for higher node degree should be a significant value, which is not the 
case. In the graph we also see that the concentration is only toward the higher 
connectivity score with no points toward the lower side, which indicates that the 
essentiality of a protein actually does not depend on the network node degree. 
4.2 Hubs As Drug Targets 
4.2.1 In current drug targets, protein interaction network hubs appear to be 
preferentially used in retrospect. 
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  Figure 4.2: Probability of hubs at varying hub degree 
In the center shaded region of Figure 4.2, we see a differential probability 
density between hubs and drug target as hubs.  The figure shows that when the 
hub is defined as indistinguishable from regular proteins (at low end where hub D 
>=2) or very high hub (D >=40), there exists no difference between the 
probabilities of hubs and hubs given drug targets [p (DT|H)]. However, this 
difference increases for medium degree hubs and is the maximum for hub node 
degree 10 – 20.   
From Figure 4.2, we conclude that medium network node degree proteins 
are more probable to be drug targets. It also promotes consideration of the 
topology of drug targets and node degree. 
4.2.2 Preferential Selection of Hub vs. Non-hub Proteins as Drug Targets 
Bayes Factor ratio [P (DT|H) / P(DT|NH)] was calculated to show the 
preferential use of drug targets in hubs vs. non-hubs. To take the arbitrary 
definition of “hub” and “non-hub” out of the picture and show the significance of 
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the ratio, we performed our analysis by varying the definitions of hubs and non-
hubs network node degrees.  
 
 Figure 4.3: Preferential use of drug targets in hubs vs. non-hubs  
 
The peak in Figure 4.3 seems to point out that neither light hubs nor heavy 
hubs are good existing “drug targets.”  However the non-hubs definition of 
network node degree <=2 and hub definition of network node degree in the range 
of 15-25 has the maximum Bayes factor.  
This gives an indication that the proteins within the network node degree 
range of 15-25 would be promising candidates for drug targets no matter how we 
define the hubs and non-hubs. 
4.2.3 Case Study on Cancer Proteins 
The analysis result of medium degree proteins as probable drug targets was tested 
on cancer proteins (see methods chapter). The subset of 66 of 382 proteins passed the 
network topology filter of 15-25. Twenty-three of 66 proteins were existing targets of 
cancer drugs (Figure 4.4). On searching the PubMed for the remaining 43 proteins, it 
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was found that 18 were reported as promising targets, with 4 as candidate targets (see 
appendix, Figure 4.21).  
 
 
    Figure 4.4 Statistics of Cancer case study 
Thus, 68% [(23+18+4)/66] of the medium degree hub proteins were either current 
targets or indicated to be promising targets for drugs. But the question is whether 
these targets are really ‘good targets’ that would cause minimal side effects when 
targeted by drugs.    
4.2.4 Probability of Hubs, Derived from Different Data Sources, to be Drug Targets 
To analyze the results on different types of interaction datasets, the study was 
extended to other databases (see method). In order to ensure uniformity across all 
datasets, a Network Connectivity Score was calculated (see method section). We 
then calculated the Bayes factor at varying definitions of non-hubs and the 
Network connectivity scores. 
Overview of all the data sources-The non-hub definition of network node degree 
<= 2 consistently gave the best Bayes factor (see appendix Figure 2-4), so it was 
considered to be the base line for non-hubs further in the study.  Of all rated 
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interactions in HAPPI, the confidence ranking of 2 and >= 2 gave the best Bayes 
factor (Figures 4.5(a) and 4.6(a), respectively). In literature co-citations, the best 
Bayes factor was for cut-off 2 (Figure 4.7(a)). However, the Bayes factor drops as 
the cut-off for citations becomes stringent (cut-off 5, 10), indicating the 
inconsideration toward the stability of interactions in selecting drug target 
proteins.  HPRD interactions gave a low Bayes factor (highest value of 2.5 
(Figure 4.8(a)). The lowest Bayes factor (less than 1.5) was for co-expression (see 
appendix Figure 4), indicating that considering co-expression as a characteristic 
while selecting drug target proteins would not be a good idea.  
Detailed Analysis of data with best Bayes Factor  
a) HAPPI – 
i. Confidence Rank =2 
Figure 4.5(a) is the Bayes factor graph for the HAPPI ranked interactions 
(confidence rank 1-5). The true measure of the candidate drug targets for 
each of the sections I, II, and III is shown in the Positive Predictive Value 
(PPV) graph (Figure 4.5(b)). Figure 4.5(c) shows the data values of the 
PPV graph and Figure 4.5(d) uses the cancer proteins to predict ‘good 
targets.’ 
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(a)         (b) 
Range(total 
proteins) 
.079 - 1 (113) .079 - .72 (75) .78 - .94(32) .95 - 1(3) 
Side effect 
score 
<= 2 >=4 <= 2 >=4 <= 2 >=4 <= 2 >=4 
MISE 63 35 43 22 15 12 3 0 
WISE 64 29 44 19 15 9 3 0 
     (c)  
Figure 4.5 (a) shows Bayes factor graph for HAPPI confidence rank (1-
5); (b) (c) shows the PPV and their data values for the ranges  
       
 
 
 
 Figure 4.5(d) Case study of ‘good targets’ 
 
Figure 4.5(a) shows the best Bayes factor (value above 3) is given by the 
interactions with the confidence ranking of 2 (low quality not 
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experimentally verified interactions). The graph shows an increase in 
Bayes factor for the score range 0.1- 0.7 (part I of Figure 4.5(a)), but then 
decreases and increases again to give a significant value for the score of 
0.95-1 (part II of Figure 4.5(a)). The ranked 2 proteins also give an overall 
70% PPV with a connectivity score of .95-1 (network node degree >= 150, 
see appendix) giving a PPV of 1 (100%) (Figure 4.5(b). However, we see 
a low Bayes factor for interactions with highest ranking (confidence rank 
of 5) in HAPPI, which are verified physical interactions. In this case, the 
Bayes factor value increases for the score range 0.2-0.6, but then declines 
for high network node degree proteins.  
We conclude from Figure 4.5 (a) that among all ranked proteins in 
HAPPI, those ranked 2 would be the best candidates for drug targets. 
However, lower PPV for the connectivity score ranges other than .95 – 1 
indicates that predicting candidate drug targets does not essentially qualify 
them to be ‘good targets’ causing minimal side effects. When applying the 
connectivity range with the best PPV to cancer proteins (Figure 4.5 (d)), it 
was found that out of 16 proteins which passed the filter, 4 were existing 
targets. Of these 4 proteins (Figure 4.5(d)), 2 were existing targets of 
approved drugs. On analyzing the side effects of the drugs targeting these 
proteins, it was found they were well tolerated. 
 The low quality interactions giving the best Bayes factor indicates 
the possibility of functional interactions being preferred over physical 
interactions in current target selection.  
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Drug target Targeting Drug 
(number of targets) 
WISE Drug Symptoms Therapeutic area 
AT1A1_HUM
AN 
(Degree =483) 
Pantoprazole(1) 1 Headache, well 
tolerated 
Short-term treatment 
of erosive 
esophagitis. 
5HT2C_HUMA
N 
(Degree =448) 
a. Mirtazapin
e(4) 
 
 
 
b. Quetiapine(
4) 
 
 
       c.     
Ziprasidone(9) 
1.03 a.Fever, Gas 
,dizziness, Stroke, 
depression 
 
b.confusion, 
headache, fever, 
death,dizziness 
 
c.constipation, 
dizziness, 
restlessness, 
diarrhea, rash 
a.Depressive 
disorder. 
 
 
 
b.schizophrenia and 
acute manic episodes 
 
c. schizophrenia 
5HT2B_HUMA
N 
(Degree= 192) 
a. Quetiapine(
4) 
 
        b.      
Eletriptan(7) 
1.06 Depression, 
dizziness, rash, 
weakness, 
depression, life-
threatening 
condition 
 
 
migraine with or 
without aura in 
adults. 
 
        Figure 4.5(e) Table for good drug target from HAPPI rank 2 where PPV = 1 
The drugs such as Ziprasidone, Quetiapine, and Eletriptan may cause 
serious side-effects but only if treated with other depression medicines or 
for dementia.  
ii. Confidence Rank Above 2, 3 and 4 
Figure 4.6 (a) shows the interactions from HAPPI with the confidence 
ranking of 2 and above, and the Positive Predictive Value (PPV) for 
different sections (I,II,III,IV) has been shown in Figure 4.6 (b).  The data 
values for PPV of all ranges are shown in Figure 4.6(c). Among all 
confidence rankings, 2 and above have the highest and the most significant 
Bayes factor. While interactions with confidence ranking of 3 also gave a 
good Bayes factor, they were not considered for further analysis as they 
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have potentially transient interactions and may not be stable. So 
interactions ranked 2 and above were further analyzed.  
        
(a)           (b)  
Range(tota
l proteins) 
.14 - 1 (119) .14 - .82 (81) .84 - .96(25) .96 - 1(5) .98 - 1(2) 
Side effect 
score 
<= 2 >=4 <= 2 >=4 <= 2 >=4 <= 2 >=4 <= 2 >=4 
MISE 67 37 43 22 13 8 4 1 2 0 
WISE 68 31 46 22 13 6 4 1 2 0 
 
   (c) 
Figure 4.6 (a) Bayes factor graph for confidence rank above (2, 3, 4); (b) (c)   
PPV and data values for HAPPI (confidence rank 2 and above); (d) Case study 
‘good targets’ 
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 We see in Figure 4.6(a) that for confidence rank >= 2 there is an 
increase in Bayes factor for the connectivity score range of 0.2-0.8, which 
decreases for a small range before increasing again (connectivity score 
range .96-1 (node degree above 220, see appendix), thus giving a high 
significant Bayes factor value. We see again that the PPV values are 
different for all ranges. Figure 4.6(b) shows the overall PPV for rank 2 and 
above to be almost 70% with 100% for the connectivity score of .98 – 1 
(network node degree >= 320, see appendix).  The interactions with 
confidence rank of 4 and above give the Bayes factor in the range 2-4, 
with only a small range above 3.  
High Bayes factor by interactions ranked 2 and above and lower by 
ranked 4 and above gives a clear indication that   functional interactions 
are being considered over stable physical interactions in drug target 
selection. This also shows that the Bayes factor value gradually starts 
decreasing as the interactions become more and more significant.  The 
different PPV values in all connectivity ranges further strengthens our 
belief that predicting candidate drug targets does not essentially 
qualify them to be ‘good targets.’ When applying the connectivity range 
filter to cancer proteins (Figure 4.6 (d)), we found that out of 31 proteins 
which passed the filter, 8 were existing targets. 
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Drug target Targeting Drug (number of 
targets) 
WISE Drug Symptoms Therapeutic area 
5HT2C_HUMAN 
(Degree =595) 
a. Mirtazapine(4) 
 
 
 
b. Quetiapine(4) 
 
 
        c.   Ziprasidone(9) 
1.03 a.Fever, Gas 
,dizziness, 
Stroke, 
depression 
 
b.confusion, 
headache, fever, 
death,dizziness 
 
c.constipation, 
dizziness, 
restlessness, 
diarrhea, rash 
a.Depressive 
disorder. 
 
 
 
b.schizophrenia 
and acute manic 
episodes 
 
c. schizophrenia 
AT1A1_HUMAN 
(Degree =483) 
Pantoprazole(1) 1 Headache, well 
tolerated 
Short-term 
treatment of 
erosive 
esophagitis. 
 
Figure 4.6(e) good drug target from HAPPI Confidence rank >= 2 with 
PPV = 1 
b) STRING (Literature co-occurrence) 
Figure 4.7 (a) shows the Bayes factor graph for literature co-occurrence with the 
cutoff of 2, 3, 5, and 10. The Positive Predictive Value (PPV) for different 
sections (I, II, III) has been shown in Figure 4.7(b) with its data values in Figure 
4.7(c). 
 
    Figure 4.7(a) 
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       (b)     
Range(total 
proteins) 
.09 - 1 (110) .09 - .4(26) .5- .8 (54) .8 - .96(14) .98 -1(2) 
Side effect 
Score 
<= 2 >=4 <= 2 >=4 <= 2 >=4 <= 2 >=4 <= 2 
MISE 61 35 21 2 28 17 7 6 0 
WISE 62 29 22 2 28 13 7 6 0 
 
      (c) 
Figure 4.7(b) and (c) shows the PPV for Co-occurrence cut-off 2 and their data 
values, respectively 
In Figure 4.7(a), we see that the co-occurrence cutoff 2 gives the highest 
Bayes factor value. However, it decreases and also falls below any significant 
value for cutoff 10 (stable interactions).  Co-occurrence cutoff 2 interactions are 
the least cited and most probably the functional interactions. Here again we see 
different PPV for different connectivity ranges. We get an overall PPV of almost 
70% (Figure 4.7(b)) with the connectivity score of .5-.8 giving better PPV than 
the higher connectivity score. 
The high Bayes factor for co-occurrence cutoff 2 further proves our point that 
stable physical interaction is not the current criteria of selecting drug target 
proteins. We also conclude from studying all the sources showing different PPV 
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for different connectivity scores above that selecting drug target does not 
necessarily make it a ‘good target.’  The high PPV for medium connectivity 
score with a low Bayes factor gives an indication that lower-to-medium degree 
proteins could be better targets causing minimal side effects if literature co-
occurrences or single interaction data sources are being considered in target 
selection.  
c) HPRD 
Figure 4.8 (a) shows the Bayes Factor graph for HPRD; the Positive Predictive 
Value (PPV) for sections I and II is shown in Figure 4.8 (b). 
    
(a)        (b)                                               
Range(total proteins) .3 - 1 (87) .3-.98(84) .98-1 (3) 
Side effect score <= 2 >=4 <= 2 >=4 <= 2 >=4 
MISE 48 27 47 25 1 2 
WISE 48 21 47 20 1 1 
 
   (c) 
Figure 4.8 (a) shows the Bayes factor; (b), (c) shows PPV graphs and data values 
for the score ranges respectively. 
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We can see from Figure 4.8(a) that an HPRD interaction does not give a 
significant Bayes factor but gives an overall 70% PPV (Figure 4.8(b)). The graph 
also shows a higher PPV for a lower-to-medium connectivity score with a lower 
PPV for a higher connectivity score. 
The low Bayes factor for HPRD interactions further proves our theory and 
we conclude that stable physical interactions are not preferred candidates for 
drug targets. The low PPV for high connectivity score is another indication that 
low-to-medium network node degree proteins would be a better source for ‘good 
targets’ when considering independent sources for interactions.  
d) High-Ranked Interactions in HAPPI 
The highly-ranked interactions in HAPPI with the confidence ranking of 5 are 
physical interactions which have been validated across several other sources. 
 
(a)         (b) 
Figure 4.9(a) and (b) shows the Bayes factor and PPV graphs for HAPPI ranked 
5 interactions, respectively. 
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From Figure 4.9(a), we see that the high-rated interactions do not give 
significant Bayes factor, which again shows that specific physical interactions are 
not considered in the selection of drug target proteins. However, medium degree 
hubs could be good targets if specific interactions or physical interactions are 
being considered. 
4.3 Current Drug Targets and Essentiality 
4.3.1 Essentiality not a Good Predictor for Selecting Drug Targets. 
We calculated the Bayes factor [p (DT|E) / p (DT|NE)] to find if essentiality plays a 
significant role in the selection of drug targets.  
 
  Figure 4.10:  Essentiality not a predictor for drug targets 
Figure 4.10 show that essentiality as a predictor gives a low Bayes factor 
value. We can also see one point with a high Bayes factor because in that 
particular range there is only one essential protein, which is also a drug target. 
The low Bayes factor value is an indication that essentiality alone would 
not prove to be a very good predictor of drug target. 
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4.3.2 Non-essential/viable Proteins as Current Drug Targets 
 
In order to analyze the trend in drug target proteins toward essentiality of proteins, 
we calculated the essentiality score (see methods) and analyzed them for drugs 
with single and multiple targets (Figures 4.12 (a) and (b).) We also compared 
them for FDA- approved and experimental drugs to see if there is a difference in 
trend (see appendix Figure 5). 
  
 (a)      (b)  
Figure 4.11 (a) Single-targeted drugs and (b) Multi-targeted drugs 
Figures (a) and (b) above clearly show that non-essential/viable proteins 
are being targeted more than essential/lethal proteins. 
By seeing the trend in approved drugs, we can conclude that non-
essential/viable proteins could be better future drug targets. 
4.4 Bad Targets 
We created a list of potential ‘bad targets’ (Figure 4.12) based on the 
target scores (WISE = 5). When analyzed for their network node degree, it was 
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found that most of them did not fall in the range of our criteria for candidates of 
good drug target node degree, which is as follows: 
o HAPPI confidence rank 2 – connectivity score .95-1 (PPV = 1) 
o Literature co-occurrence 2- connectivity score .09-.4 (PPV=.91) 
 
Drug targets  Targeting 
Drugs(WISE)  
Degree rank=2   
(Connectivity score)  
Lit co-occurrence 2 
(Connectivity 
score)  
AOFA_HUMAN    <.95  >.4  
CD52_HUMAN     1(5)  <.95  >.4  
PRGR_HUMAN     1(5)  <.95  >.4  
V2R_HUMAN      1(5)  <.95  >.4  
 PDE4B_HUMAN    1(5)  <.95  >.4  
NEU2_HUMAN     1(5)  <.95  >.4  
KCNK2_HUMAN    1(5)  <.95  >.4  
PYRD_HUMAN     1(5)  <.95  >.4  
ACES_HUMAN     2(5)  <.95  >.4  
ACET_HUMAN     8(5)    
 
  Figure 4.12 List of ‘bad targets’ and their connectivity score 
4.5 CONCLUSION 
• Network Biology perspective to drug discovery is necessary when selecting 
candidate drug targets and could bring forth a new approach to target selection.  
• Selecting drug targets does not necessarily qualify them as ‘good targets.’ 
• Functional interactions are preferred in the selection of candidate drug targets. 
• Integrated sources are a better source for interactions of candidate drug targets. 
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• Essentiality in itself is not a very good predictor for selection of targets. 
• Current drug targets tend to target non-essential proteins. 
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CHAPTER 5 
     DISCUSSION 
 The network biology perspective in studying candidate drug targets is necessary 
due to the complexity of molecular systems.  To perform our study about drug selection 
from the network biology perspective, we used the emerging biomolecular data sets, 
which included drug and target, protein interaction, literature co-occurrence, drug side 
effects and essentiality. We used Bayes factor and Positive Predictive Values to examine 
the use of certain network properties, such as network node degrees and essentiality, to 
predict candidate drug targets. Using this method, we were able to find the best network 
connectivity scores for current targets; this method also will assist in predicting candidate 
drug targets.  
We also showed the distinction between drug targets and ‘good drug targets.’ We 
were able to predict the connectivity scores for ‘good targets,’ which could be used to 
find probable drug targets causing minimum side effects. We ranked the drugs based on 
their side effects in an effort to standardize them. By taking into account the aggregated 
side effect scores of all FDA-approved drugs, we developed a metric for their target 
proteins. In the process, we developed the essentiality database. 
 The low availability of side effect data and lack of common terminology for the 
side effects, however, created some problems. We had to score them per our 
understanding, which may not have resulted in the best scores for a particular description 
of side effect. The essentiality database created was not a true representation of low node 
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degree proteins but could not be helped because of the low availability of the essentiality 
data.  
 There is a need for detailed side effect information of drugs with standard 
terminology. An integrated database for drugs, their side effects, drug targets and their 
interacting partners, along with their homolog proteins and their pathway details, would 
be a good source for analyzing drug targets. 
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APPENDIX 
 
 
1. Literature mining for potential cancer Drug Targets 
 
Drug target 
protein in 
filter range 
Node 
degree 
Gene 
name 
Current 
drug 
target 
Literature references 
BRAF1_HU
MAN 
25 BRAF  use of this gene as target for an effective cancer therapy. 
IMA2_HU
MAN 
25 KPNA
2 
  
MET_HUM
AN 
25 MET Y "ETV6-NTRK3—Trk-ing the primary event in human secretory breast 
cancer"- role of Trk signaling in breast cancer and also suggest a 
target for drug development. 
NTRK3_HU
MAN 
25 NTRK
3 
  
TIF1A_HU
MAN 
25 TIF1   
TRAF4_HU
MAN 
25 TRAF
4 
 "P300/CBP acts as a coactivator to cartilage homeoprotein-1 (Cart1), 
"lysine may be a common target for HAT of p300/CBP for these 
proteins. 
TSC1_HUM
AN 
25 TSC1   
TSHR_HU
MAN 
25 TSHR Y  
DHSB_HU
MAN 
24 SDHB  succinate dehydrogenase deficiency may be the cause of a subgroup 
of GISTs and this offers a therapeutic target for GSTs  
Gastrointestinal stromal tumors(GISTs) 
KCY_HUM
AN 
24  Y  
MAF_HUM
AN 
24 MAF   
PDGFB_HU
MAN 
24 PDGF
B 
  
PGFRA_H
UMAN 
24 PDGF
RA 
 FIP1L1-PDGFRA fusion gene  are excellent candidates for treatment 
with tyrosine kinase inhibitors even if they present with an aggressive 
phenotype such as AML." 
TEC_HUM
AN 
24 TEC   
TOP1_HU
MAN 
24 TOP1   
BLM_HUM
AN 
23 BLM   
GATA1_HU
MAN 
23 GATA
1 
  
INAR1_HU
MAN 
23 IFNA
R1 
Y  
FGFR2_HU
MAN 
22 FGFR2 Y  
FLT3_HUM
AN 
22 FLT3  FLT3/ITD and can be a therapeutic target in the treatment of AML 
with FLT3/ITD". Okamoto, M.Hayakawa, F.Miyata 
FOXO1_HU
MAN 
22 FOXO
1A 
  
HS90B_HU
MAN 
22 HSPC
B 
Y  
MLH1_HU
MAN 
22 MLH1   
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MOES_HU
MAN 
22 MSN   
PA1B3_HU
MAN 
22 PAFA
H1B3   
  
PRGR_HU
MAN 
22 PGR   Y  
PTMA_HU
MAN 
22 PTMA  PTMA expression in RMS biopsy samples might prove to be an 
effective diagnostic marker for this disease 
TSC2_HUM
AN 
22 TSC2   
ADT3_HU
MAN 
21  Y  
FGFR3_HU
MAN 
21 FGFR3   
LDLR_HU
MAN 
21  Y  
NF1_HUM
AN 
21 NF1   
RBTN2_HU
MAN 
21 LMO2   
ALK_HUM
AN 
20 ALK Y  
BCL10_HU
MAN 
20 BCL10   
IMDH1_HU
MAN 
20  Y  
MERL_HU
MAN 
20 NF2  “A clue to the therapy of neurofibromatosis type 2: NF2/merlin is a 
PAK1 inhibitor” 
NPM_HUM
AN 
20 NPM1  NPMI mutation may represent a new target to monitor minimal 
residual disease in AML and a potential candidate for alternative and 
targeted treatments 
PPAT_HU
MAN 
20 PPAR
G 
Y  
ADT1_HU
MAN 
19  Y  
BTG1_HU
MAN 
19 BTG1  BTG1 could be used as a potential treatment-related biomarker for 
monitoring the therapy effect  
FLI1_HUM
AN 
19 FLI1   
MTG8_HU
MAN 
19 CBFA2
T1 
 RUNX1-CBFA2T1 is a promising and leukaemia-specific target for 
molecularly defined therapeutic approaches. 
TYSY_HU
MAN 
19  Y  
METH_HU
MAN 
18  Y  
RARB_HU
MAN 
18    
SAHH_HU
MAN 
18  Y  
SOAT1_HU
MAN 
18  Y  
TCPE_HU
MAN 
18 CCT5  CCT5 clinically useful in identifying the subset of breast cancer 
patients who may or may not benefit from docetaxel treatment. 
WRN_HUM
AN 
18 WRN  a possible therapeutic role for WRN as an anti-cancer target, and 
highlight the importance of WRN protein status for tumorigenesis 
and clinical treatments of patients 
ETV6_HU
MAN 
17 ETV6   
IRF4_HUM
AN 
17 IRF4   IRF4 can be used as a molecular marker of clinical subtype in ATL.' 
LOX15_HU
MAN 
17 ALOX
15 
  
PAX3_HU
MAN 
17 PAX3  'PAX3 as a promising target for immunotherapy of cancer.' 
TCPD_HU
MAN 
17 CCT4     
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ATF1_HU
MAN 
16 ATF1   
CBX3_HU
MAN 
16 CBX3   
CO1A2_HU
MAN 
16 COL1
A2   
  
FOXO3_HU
MAN 
16 FOXO
3A 
 FOXO1 protein appears to be a promising target for future drug 
discovery and cancer therapy. 
MEN1_HU
MAN 
16 MEN1   
PRLR_HU
MAN 
16  Y  
RXRB_HU
MAN 
16 RXRB   
ANXA1_HU
MAN 
15 ANXA
1  
Y  
FANCC_H
UMAN 
15 FANC
C 
 The impact of Fanconi gene defects on drug and irradiation 
sensitivity renders these genes promising targets for a specific, 
genotype-based therapy for individual cancer patients, providing a 
strong rationale for clinical trials. 
PIM1_HUM
AN 
15 PIM1 Y  
TPM3_HU
MAN 
15 TPM3  TM gene expression is a target of oncogene action or is an indirect 
consequence. 
 
2. Bayes Factor at varying definitions of Hub and Non-Hub. 
a) HAPPI Confidence rating 2-5 respectively (Figure 1 a-d). 
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   (c)        (d)  
Figure 1:  Bayes factor graph for (a) confidence rating 2; (b) confidence 
rating 3; (c) confidence rating 4 (d) confidence rating 5 
 
b) HAPPI Confidence rating above 2, 3 and 4 respectively (Figure 2 a-c). 
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       (c) 
Figure 2: Bayes factor graph for (a) confidence rating above 2; (b) confidence 
rating above 3; (c) confidence rating above 4 
c) Literature co-occurrence cut-off 1, 2, 5, 10 (Figure 3 a-d) 
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   (c )          (d)  
Figure 3:  Literature co occurrence (a) cut-off 2; (b) cut-off 3; (c) cut-off 5; (d) 
cut-off 10 
 
d) Co-expression (Figure 4 a-b) 
 
(a)        (b)  
Figure 4 (a) Conserved Co-expression; (b) Human co-expression 
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3. Co-relation between essentiality of targets and Multi targeted Drugs (Figure 5 a-c). 
 
 
(a)  
 
 
(b)      (c)  
Figure 5 (a) All Drugs; (b) Approved Drugs; (c) Experimental Drugs 
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